Nasdaq
$0.8636▼ 0.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $53.5MShares out 61.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.2After-hours26.10.03 05:204Ownership#●●●
PLIANT THERAPEUTICS, INC.
Pliant Therapeutics (PLRX) insider David Raben filed a Form 4 report regarding changes in beneficial ownership of securities effective October 1, 2026. This filing serves as a standard disclosure of the insider's equity position adjustment.…more
$0.8636-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:193Ownership
PLIANT THERAPEUTICS, INC.
David Raben, an officer of Pliant Therapeutics, Inc., has filed a Limited Power of Attorney authorizing company representatives to manage his SEC filing obligations. Executed on September 29, 2026, this document grants the designated attorneys-in-fact the authority to prepare and submit required ownership and transaction reports via the SEC's EDGAR system.…more
$0.8636-0.12%vs prev closeView filingShare - 8.17Pre-market26.08.15 10:31filedSCHEDULE 13GOwnership
PLIANT THERAPEUTICS, INC.
Adar1 Capital Management, LLC and Daniel Schneeberger have entered into a Joint Filing Agreement to report their collective ownership of Pliant Therapeutics, Inc. common stock via Schedule 13G. This agreement was officially executed on August 14, 2026, to facilitate the joint reporting of their shareholdings.…more
$0.8636-0.12%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:30#●●●#●●●
Pliant Therapeutics Appoints Craig Blanchette as SVP of Research (siRNA)…more
Pliant Therapeutics has appointed RNAi drug discovery expert Dr. Craig Blanchette as Senior Vice President of Research. This appointment is intended to strengthen the company's proprietary integrin-mediated drug delivery platform.…more
$0.8636-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 5d agoAfter-hours26.10.20 05:05
●●●●●●●● ●●●●● ●●●●●●
Pliant Therapeutics will present Phase 1b clinical data for its solid tumor candidate PLN-101095 at the upcoming ESMO Congress 2026. This presentation serves as an update on ongoing research and is considered a neutral event for the stock.…more
$0.8636-0.12%vs prev close - 9.30After-hours26.10.01 05:10
●●●●●●●● ●●●●● ●●●●●●
Pliant Therapeutics has appointed oncology drug development expert Dr. David Raben as its new Chief Medical Officer. The company aims to leverage his expertise to accelerate the clinical development of its pipeline, including PLN-101095.…more
$0.8636-0.12%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report